247035-26-3

Downstream Products

• 247035-27-4 Methyl 2,3-difluoro-4-{4(methanesulfonyloxy)piperidin-1-yl}benzoate 
• 247034-24-8 tert-butyl (2S)-benzenesulfonylamino-3-[2,3-difluoro-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 247035-31-0 2,3-difluoro-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid 
• 247035-30-9 methyl 2,3-difluoro-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate 
• 247035-28-5 4-(4-azido-piperidin-1-yl)-2,3-difluoro-benzoic acid methyl ester 
• 247035-29-6 methyl (4-aminopiperidin-1-yl)-2,3-difluorobenzoate 

Relevant academic research and scientific papers

Aminopiperidine derivates as integrin αvβ3 antagonists

An objective of the present invention is to provide compounds having integrin αvβ3antagonistic activity, cell adhesion inhibitory activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and, therapeutic agents for treating cardiovascular diseases, angiogenesis-related diseases, cerebrovascular diseases and the like and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic group containing two nitrogen atoms or the like; D represents >NH2, >CH2or the like; X and Z represent CH or a nitrogen atom; R7and R8represent alkyl, halogen or the like; Q represents >C═O, >CH2or the like; R9represents H, alkyl, aralkyl or the like; R10represents H, alkynyl or the like; R11represents H, substituted amino or the like; R12represents H or alkyl; m is 0 to 5; n is 0 to 4; p and q are each 1 to 3; and r is 0 or 1.